Integrating pharmacogenomics- metabolomics towards realising personalised medicine for colorectal cancer patients treated with 5-fluorouracil / Hazwanie Hashim

Integrating pharmacogenomics- metabolomics towards realising personalised medicine for colorectal cancer patients treated with 5-fluorouracil / Hazwanie Hashim

Colorectal cancer (CRC) is one of the most common cancers among men and women in Malaysia. 5-flurouracil (5-FU)/leucovorin is the standard chemotherapy for colorectal cancer and various other types of cancer including breast, head and neck cancers. However, standard method for dosing 5-fluorouracil...

Full description

Bibliographic Details
Main Author: Hashim, Hazwanie
Format: Book Section
Language:English
Published: Institute of Graduate Studies, UiTM 2012
Subjects:
Malaysia
Online Access:http://ir.uitm.edu.my/id/eprint/19122/
http://ir.uitm.edu.my/id/eprint/19122/1/ABS_HAZWANIE%20HASHIM%20TDRA%20VOL%201%20IGS%2012.pdf
id uitm-19122
recordtype eprints
spelling uitm-191222018-06-11T02:37:26Z http://ir.uitm.edu.my/id/eprint/19122/ Integrating pharmacogenomics- metabolomics towards realising personalised medicine for colorectal cancer patients treated with 5-fluorouracil / Hazwanie Hashim Hashim, Hazwanie Malaysia Colorectal cancer (CRC) is one of the most common cancers among men and women in Malaysia. 5-flurouracil (5-FU)/leucovorin is the standard chemotherapy for colorectal cancer and various other types of cancer including breast, head and neck cancers. However, standard method for dosing 5-fluorouracil (5-FU) still lacks accuracy and reliability. In addition to the body surface area index (BSA) that is currently used in dosing regimen, other factors such as genotype, age, gender and drugdrug interaction needs to be accounted. We explore the value of pharmacogenomics and metabolomics in personalising medicine in patients treated with 5-FU. We intended to profile both the genetics and metabolomics markers that could be useful in the clinical monitoring of patients’ responses towards 5-FU and its disease. Genetic polymorphism of DPYD and UGT1A1 show interethnic differences among the populations studied. The frequency of DPYD*5, DPYD 1896 T>C, UGT1A1*28 and UGT1A1*6 was high in this study. Patients who experienced neutropenia had significantly higher serum concentration of 5-FU as compared to those who did not have it (Mann Whitney-U test, p-value= 0.031). Institute of Graduate Studies, UiTM 2012 Book Section PeerReviewed text en http://ir.uitm.edu.my/id/eprint/19122/1/ABS_HAZWANIE%20HASHIM%20TDRA%20VOL%201%20IGS%2012.pdf Hashim, Hazwanie (2012) Integrating pharmacogenomics- metabolomics towards realising personalised medicine for colorectal cancer patients treated with 5-fluorouracil / Hazwanie Hashim. In: The Doctoral Research Abstracts. IPSis Biannual Publication, 1 (1). Institute of Graduate Studies, UiTM, Shah Alam.
repository_type Digital Repository
institution_category Local University
institution Universiti Teknologi MARA
building UiTM Institutional Repository
collection Online Access
language English
topic Malaysia
spellingShingle Malaysia
Hashim, Hazwanie
Integrating pharmacogenomics- metabolomics towards realising personalised medicine for colorectal cancer patients treated with 5-fluorouracil / Hazwanie Hashim
description Colorectal cancer (CRC) is one of the most common cancers among men and women in Malaysia. 5-flurouracil (5-FU)/leucovorin is the standard chemotherapy for colorectal cancer and various other types of cancer including breast, head and neck cancers. However, standard method for dosing 5-fluorouracil (5-FU) still lacks accuracy and reliability. In addition to the body surface area index (BSA) that is currently used in dosing regimen, other factors such as genotype, age, gender and drugdrug interaction needs to be accounted. We explore the value of pharmacogenomics and metabolomics in personalising medicine in patients treated with 5-FU. We intended to profile both the genetics and metabolomics markers that could be useful in the clinical monitoring of patients’ responses towards 5-FU and its disease. Genetic polymorphism of DPYD and UGT1A1 show interethnic differences among the populations studied. The frequency of DPYD*5, DPYD 1896 T>C, UGT1A1*28 and UGT1A1*6 was high in this study. Patients who experienced neutropenia had significantly higher serum concentration of 5-FU as compared to those who did not have it (Mann Whitney-U test, p-value= 0.031).
format Book Section
author Hashim, Hazwanie
author_facet Hashim, Hazwanie
author_sort Hashim, Hazwanie
title Integrating pharmacogenomics- metabolomics towards realising personalised medicine for colorectal cancer patients treated with 5-fluorouracil / Hazwanie Hashim
title_short Integrating pharmacogenomics- metabolomics towards realising personalised medicine for colorectal cancer patients treated with 5-fluorouracil / Hazwanie Hashim
title_full Integrating pharmacogenomics- metabolomics towards realising personalised medicine for colorectal cancer patients treated with 5-fluorouracil / Hazwanie Hashim
title_fullStr Integrating pharmacogenomics- metabolomics towards realising personalised medicine for colorectal cancer patients treated with 5-fluorouracil / Hazwanie Hashim
title_full_unstemmed Integrating pharmacogenomics- metabolomics towards realising personalised medicine for colorectal cancer patients treated with 5-fluorouracil / Hazwanie Hashim
title_sort integrating pharmacogenomics- metabolomics towards realising personalised medicine for colorectal cancer patients treated with 5-fluorouracil / hazwanie hashim
publisher Institute of Graduate Studies, UiTM
publishDate 2012
url http://ir.uitm.edu.my/id/eprint/19122/
http://ir.uitm.edu.my/id/eprint/19122/1/ABS_HAZWANIE%20HASHIM%20TDRA%20VOL%201%20IGS%2012.pdf
first_indexed 2023-09-18T23:01:54Z
last_indexed 2023-09-18T23:01:54Z
_version_ 1777418228835811328

Similar Items